PX1 Research provides USA-manufactured CJC-1295 with DAC (Drug Affinity Complex) optimized for laboratory evaluation of growth hormone secretagogue pathways. Every synthesis lot undergoes rigorous third-party analytical verification, including RP-HPLC purity assessment, mass spectrometry sequence confirmation, and endotoxin testing to support reliable, reproducible preclinical data.
PX1 Research provides USA-manufactured CJC-1295 with DAC (Drug Affinity Complex) optimized for laboratory evaluation of growth hormone secretagogue pathways. Every synthesis lot undergoes rigorous third-party analytical verification, including RP-HPLC purity assessment, mass spectrometry sequence confirmation, and endotoxin testing to support reliable, reproducible preclinical data.
CJC-1295 with DAC is a synthetic 30-amino-acid peptide derivative of growth-hormone-releasing hormone (GHRH) modified with a maleimide derivative known as the Drug Affinity Complex (DAC). When investigators choose to buy CJC-1295 with DAC for bench research, they acquire a long-acting GHRH agonist engineered to covalently bind to circulating serum albumin, extending its biological half-life from minutes to several days in experimental models.
In preclinical research models, CJC-1295 with DAC acts directly on anterior pituitary somatotrophs to stimulate prolonged synthesis and secretion of endogenous growth hormone (GH) and downstream insulin-like growth factor 1 (IGF-1). This sustained pharmacodynamic profile allows researchers to explore metabolic, tissue repair, and nitrogen retention pathways over extended observation windows without the rapid clearance characteristic of unmodified native GHRH.
The primary sequence of CJC-1295 with DAC is based on the functional N-terminal 29-amino-acid fragment of GHRH (Growth Hormone Releasing Hormone, 1-29), stabilized by specific amino acid substitutions at positions 2, 8, 15, and 27. These modifications confer enzymatic resistance against dipeptidyl peptidase IV (DPP-IV) cleavage, a primary pathway responsible for the rapid degradation of native peptide hormones in biological fluids.
The critical distinguishing feature of this compound is the bioconjugation of a Lysine residue at position 30 to a 3-maleimidopropionic acid reactive group—the Drug Affinity Complex (DAC). Upon exposure to biological matrices, the maleimide group reacts rapidly and specifically with the free thiol group of Cys34 on circulating serum albumin. This irreversible bioconjugation creates a stable macromolecular complex.
Because albumin possesses an extended physiological half-life (~19–20 days in mammalian systems), the conjugated CJC-1295 molecule evades renal filtration and enzymatic breakdown. When researchers evaluate GHRH receptor analogs in cell culture or animal assays, this bioconjugation alters the kinetic profile from short-term pulsatile activation to sustained receptor occupancy.
At the cellular level, CJC-1295 with DAC functions as a selective agonist at the GHRH receptor (GHRHR), a Class B G-protein-coupled receptor predominantly expressed on anterior pituitary somatotrophs. Activation of GHRHR triggers the Gs alpha subunit, stimulating transmembrane adenylyl cyclase to catalyze the conversion of ATP to cyclic adenosine monophosphate (cAMP).
Elevated intracellular cAMP levels activate Protein Kinase A (PKA), leading to the phosphorylation of CREB (cAMP response element-binding protein). This intracellular signaling cascade upregulates transcription factors governing growth hormone gene expression and opens voltage-gated L-type calcium channels, promoting exocytosis of pre-stored GH vesicles.
Unlike short-acting secretagogues, the persistent receptor interaction mediated by CJC-1295 with DAC leads to continuous baseline stimulation of GH release while maintaining responsiveness to physiological negative feedback loops such as somatostatin. Downstream activation leads to hepatocyte production of insulin-like growth factor 1 (IGF-1), enabling researchers to study the biological effects of sustained IGF-1 elevation on peripheral tissues.
In vitro and animal model studies have demonstrated that CJC-1295 with DAC significantly elevates baseline serum GH concentrations and produces dose-dependent increases in total circulating IGF-1. Preclinical literature shows that a single administration in rodent models can maintain elevated plasma concentrations of IGF-1 for over seven to ten days.
Research literature investigating tissue repair pathways highlights several key areas of interest for investigators evaluating this compound:
• Muscle Protein Synthesis and Nitrogen Balance: In rodent models of catabolism, sustained GHRH pathway activation correlates with enhanced satellite cell proliferation and increased skeletal muscle protein accretion.
• Connective Tissue and Extracellular Matrix Remodeling: Research indicates that elevated IGF-1 signaling accelerates collagen cross-linking and fibroblast activity in connective tissue injury models.
• Adipose Tissue Metabolism: Preclinical data demonstrate increased lipolysis in isolated adipocytes via GHRH-mediated down-regulation of lipid accumulation enzymes, supporting studies on energy substrate utilization.
• Bone Mineral Density Pathways: Animal studies investigating metabolic bone disease demonstrate that long-term GH/IGF-1 pathway stimulation enhances osteoblast activity and bone remodeling indices.
When designing research protocols, investigators must select secretagogues that match the desired pharmacokinetic profile. The inclusion of the Drug Affinity Complex fundamentally differentiates this compound from non-conjugated GHRH derivatives and selective ghrelin receptor agonists.
Below is a comparative breakdown of CJC-1295 with DAC against related research compounds frequently evaluated in growth axis investigations:
• CJC-1295 Without DAC (Modified GRF 1-29): Lacks the maleimide reactive group. It exhibits a short plasma half-life (~30 minutes) and produces short, acute GH pulses mimicking physiological GHRH bursts.
• Sermorelin: The truncated 29-amino-acid native sequence of GHRH. Rapidly degraded by DPP-IV, requiring frequent administration in experimental protocols to maintain receptor stimulation.
• Ipamorelin: A selective growth hormone secretagogue receptor (GHSR-1a) agonist rather than a GHRH analog. Operates via a distinct, synergistic pathway without triggering cortisol or prolactin release.
Choosing between these compounds depends on whether the experimental model requires sustained, tonic elevation of the growth axis (CJC-1295 with DAC) or transient, pulsatile secretagogue signaling.
For empirical research to produce publishable, reproducible results, peptide purity and structural fidelity are non-negotiable. Substandard peptides containing truncation sequences, residual trifluoroacetic acid (TFA), or organic solvents introduce uncontrolled variables into cell culture and animal experiments.
PX1 Research enforces strict quality control standards for every lot of CJC-1295 with DAC:
• Reverse-Phase HPLC (RP-HPLC): Determines chromatographic purity. Every lot offered by PX1 Research is verified to exceed 98% purity (typically >99%), ensuring minimal peptide fragment contamination.
• Electrospray Ionization Mass Spectrometry (ESI-MS): Confirms exact molecular mass (MW: 3647.28 Da for CJC-1295 with DAC), verifying correct sequence assembly and maleimide conjugation.
• Lot-Specific Certificates of Analysis (COA): Every vial is linked to a downloadable COA performed by an independent ISO 17025 accredited analytical laboratory in the USA.
Researchers can inspect the raw HPLC chromatograms and mass spectra directly on our PX1 Research analytical testing standards verification portal before incorporating material into study protocols.
Bacterial endotoxins (lipopolysaccharides, LPS) present a severe confounding variable in cell culture and physiological research. Injected or applied endotoxins trigger immune cascades, NF-kB activation, and inflammatory cytokine release, distorting research results on tissue repair or cellular metabolism.
All CJC-1295 with DAC batches produced for PX1 Research undergo LAL (Limulus Amebocyte Lysate) kinetic chromogenic testing to verify endotoxin levels below 0.5 EU/mg. Our peptides are synthesized in state-of-the-art GMP-compliant facilities and lyophilized under aseptic conditions to safeguard cell viability and experimental integrity.
To preserve structural integrity and prevent degradation, CJC-1295 with DAC must be handled following standard biochemical laboratory procedures:
1. Lyophilized Storage: Unreconstituted vials should be stored at -20°C for short-to-medium term storage, or -80°C for long-term storage, protected from light and moisture exposure.
2. Reconstitution: Allow the vial to equilibrate to room temperature prior to reconstitution to minimize condensation. Reconstitute using sterile Bacteriostatic Water (0.9% benzyl alcohol) or laboratory-grade Sterile Saline based on protocol needs.
3. Solubilization: Inject the solvent along the inner glass wall of the vial. Gently swirl the vial until the cake is fully dissolved. Never vortex high-purity peptides, as mechanical shear stress can denature secondary structures.
4. Aliquoting & Post-Reconstitution Storage: Following reconstitution, aliquot into single-use polypropylene tubes to prevent repeat freeze-thaw cycles. Store reconstituted solution at 2°C to 8°C for up to 30 days, or freeze aliquots at -80°C for extended study protocols.
For additional laboratory handling guidance and buffer compatibility data, review our high-purity research peptides hub.
When institutional buyers and lab directors need to buy CJC-1295 with DAC, sourcing reliability, batch consistency, and rapid delivery are essential to maintain project timelines. PX1 Research operates domestic fulfillment centers in California and Arizona, providing same-day dispatch for orders placed before 3:00 PM EST Monday through Friday.
We support academic institutes, biotechnology firms, and contract research organizations (CROs) with bulk scale-up capabilities. Laboratories requiring recurring volume pricing or custom synthesis parameters can submit inquiries through our dedicated wholesale lab account portal.
What is the primary difference between CJC-1295 with DAC and CJC-1295 without DAC?
The primary difference lies in the presence of the Drug Affinity Complex (DAC), a maleimide derivative attached to Lys30. DAC enables CJC-1295 to bind covalently to circulating albumin, extending its biological half-life from approximately 30 minutes (without DAC) to over 6–8 days in preclinical models.
What is the purity level of CJC-1295 with DAC supplied by PX1 Research?
Every lot of CJC-1295 with DAC sold by PX1 Research is verified by independent ISO 17025 accredited laboratories to exceed 98% purity, with most batches achieving >99% purity as measured by RP-HPLC.
How can I access the Certificate of Analysis (COA) for my specific peptide lot?
Lot-specific COAs featuring raw HPLC chromatograms, mass spectrometry reports, and endotoxin assay results are accessible on our website by entering the lot number printed on your product label.
What are the recommended endotoxin limits for cell culture research?
PX1 Research guarantees endotoxin levels below 0.5 EU/mg across our product line, preventing endotoxin-induced cytokine release or receptor artifacting during in vitro and cell-based assays.
How should reconstituted CJC-1295 with DAC be stored in the lab?
Once reconstituted with sterile bacteriostatic water, the liquid solution should be kept at 2°C to 8°C and used within 30 days. For longer storage, aliquot the solution into single-use tubes and freeze at -80°C to avoid repeated freeze-thaw cycles.
Where does PX1 Research ship CJC-1295 with DAC from?
All PX1 Research compounds are manufactured in USA-based facilities and dispatched directly from our fulfillment hubs located in California and Arizona. Orders placed Monday through Friday before 3 PM EST ship same-day.
Can CJC-1295 with DAC be combined with Ipamorelin in preclinical assays?
Yes, in preclinical literature, GHRH analogs (such as CJC-1295) and GHSR agonists (such as Ipamorelin) are frequently evaluated together to investigate synergistic GH secretion via two complementary cell signaling pathways.
Are PX1 Research compounds intended for human use?
No. All products sold by PX1 Research, including CJC-1295 with DAC, are strictly intended for laboratory in vitro and preclinical research applications. They are not for human or animal consumption, diagnostic, or therapeutic use.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.